In the ARK 2025 report, JingTai Technology was mentioned:

AI and treatment are changing the economics of drug development

• AI-driven development and disease treatment can improve the return on R&D investment.

• Traditional assets typically achieve breakeven in the first phase, but AI-accelerated drug development can unlock significant value earlier.

• Comparison of drug development models:

• Traditional drugs, traditional development: low returns, breakeven achieved upon commercialization.

• AI-accelerated traditional drugs: higher return on investment, breakeven achieved earlier.

• AI-accelerated treatments: highest return potential, significantly higher value at all clinical stages.

• Representative companies: Beam, Crispr Tx, Editas, Intellia, Prime, Abcellera, Generate Bio, Isomorphic Lab, Lantern Pharma, Recursion, Roivant Sciences, Xtalpi ($XTALPI(02228.HK))

Xtalpi is the only Chinese company mentioned in this relevant field.